Delivery Order SPE2DB22D1202-SPE2DB25FVCT5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,910.41 to AmerisourceBergen Drug Corp for the supply of Lamotrigine ER 250 mg tablets (30-count packages). This contract, awarded on August 5, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $1,119.28 to AmerisourceBergen Drug Corp for Lamotrigine ER 300 mg tablets (30-count) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price, competitively awarded delivery order will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is executed under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,336.23 to AmerisourceBergen Drug Corp for Lamotrigine ER 300 mg tablets (30-count supply) on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Lamotrigine is a neurological medication commonly used to treat epilepsy and bipolar...
- The Defense Logistics Agency awarded a $3,943.17 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lamotrigine ER 250 mg tablets (30-count units), with an ultimate completion date of August 13, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $4,824.31 to AmerisourceBergen Drug Corp for Lamotrigine ER 50 mg tablets (30-count) on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Lamotrigine is a neurological medication commonly used for seizure management and bipolar...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lamotrigine ER 250 mg tablets (30-count supply) valued at $3,688.24, with an award date of August 12, 2025, and ultimate completion date of August 13, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Lamotrigine is a neurological medication commonly used in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of Lamotrigine ER 100 mg tablets in quantities of 30 units, with a ceiling value of $1,163.95. This competitively awarded, firm fixed-price delivery order is scheduled for completion by June 4, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, indicating open competition among...
- The Defense Logistics Agency awarded a delivery order valued at $1,392.59 to AmerisourceBergen Drug Corp for Lamotrigine ER 100 mg tablets (30-count supply) on August 26, 2025, with completion expected by August 27, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency has awarded a delivery order valued at $1,638.18 to AmerisourceBergen Drug Corp for the supply of Lamotrigine ER 250 mg tablets in quantities of 30 units. The contract is structured as a firm fixed price delivery order with an ultimate completion date of June 2, 2025. This award was made through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order valued at $1,323.38 to AmerisourceBergen Drug Corp for Lamotrigine ER 200 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. Lamotrigine is a generic anticonvulsant and mood-stabilizing medication commonly used in military...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVCT5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,595.37 to AmerisourceBergen Drug Corp for Lamotrigine ER 250 mg tablets in 30-count units. This competitively awarded, firm fixed price delivery order was finalized on June 20, 2025, with an ultimate completion date of June 23, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this procurement. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal military and healthcare systems, AmerisourceBergen leverages this comprehensive global pharmaceutical support vehicle to supply a broad spectrum of medications and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. The Lamotrigine ER delivery demonstrates the company's role in providing neurological treatment pharmaceuticals to support military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.6k | 6/20/25 |